Ever Supreme Bio Technology (6712) reported revenue of NT$112.1 million for Oct 2026, +0.8% year on year and +1.5% from the previous month. Revenue for Jan–Oct 2026 was NT$891.6 million (+15.2% year on year).
Year-on-year revenue growth: 25+ months in a row. →
In Oct 2026, it ranked No. 69 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$112.1 million | +0.8% | +1.5% |
| Sep 2026 | NT$110.5 million | +21.3% | +0.8% |
| Aug 2026 | NT$109.6 million | +21.1% | +10.5% |
| Jul 2026 | NT$99.2 million | +20.7% | +5.7% |
| Jun 2026 | NT$93.9 million | +16.1% | +3.6% |
| May 2026 | NT$90.6 million | +25.0% | +6.3% |
| Apr 2026 | NT$85.2 million | +26.2% | +21.6% |
| Mar 2026 | NT$70.1 million | +15.1% | +12.7% |
| Feb 2026 | NT$62.2 million | +3.4% | +6.9% |
| Jan 2026 | NT$58.2 million | +2.4% | -54.5% |
| Dec 2025 | NT$128 million | +0.7% | +2.4% |
| Nov 2025 | NT$125 million | +1.3% | +12.5% |
| Oct 2025 | NT$111.1 million | +12.2% | +22.0% |
| Sep 2025 | NT$91.1 million | +1.2% | +0.6% |
| Aug 2025 | NT$90.5 million | +3.1% | +10.1% |
| Jul 2025 | NT$82.2 million | +17.1% | +1.7% |
| Jun 2025 | NT$80.9 million | +30.2% | +11.6% |
| May 2025 | NT$72.5 million | +20.5% | +7.3% |
| Apr 2025 | NT$67.5 million | +20.5% | +10.9% |
| Mar 2025 | NT$60.9 million | +10.6% | +1.2% |
| Feb 2025 | NT$60.2 million | +9.6% | +5.8% |
| Jan 2025 | NT$56.9 million | +6.3% | -55.3% |
| Dec 2024 | NT$127.1 million | +56.8% | +2.9% |
| Nov 2024 | NT$123.5 million | +41.0% | +24.6% |
| Oct 2024 | NT$99.1 million | +13.2% | +10.1% |
Jan–Oct 2026 cumulative: NT$891.6 million (+15.2% YoY)
Other Biotech & Medical companies
Compare with peers: Ever Supreme Bio Technology vs PEC / Ever Supreme Bio Technology vs Lotus Pharm / Ever Supreme Bio Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16